Corline Biomedical AB reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was SEK 8.01 million compared to SEK 10.95 million a year ago. Revenue was SEK 8.17 million compared to SEK 10.96 million a year ago. Net income was SEK 0.179 million compared to SEK 1.97 million a year ago. Basic earnings per share from continuing operations was SEK 0.01 compared to SEK 0.09 a year ago. Diluted earnings per share from continuing operations was SEK 0.01 compared to SEK 0.09 a year ago.
For the nine months, sales was SEK 26.79 million compared to SEK 22.57 million a year ago. Revenue was SEK 26.98 million compared to SEK 22.79 million a year ago. Net loss was SEK 1.21 million compared to net income of SEK 1.99 million a year ago. Basic loss per share from continuing operations was SEK 0.06 compared to basic earnings per share from continuing operations of SEK 0.09 a year ago. Diluted loss per share from continuing operations was SEK 0.06 compared to diluted earnings per share from continuing operations of SEK 0.09 a year ago.